India's pharmaceutical sector continues to strengthen its global position with a series of positive developments in mid-2026. From extending its lead over China in US FDA drug master filings to…
The long-anticipated US-India bilateral trade deal is moving toward finalization, with major implications for India's generic pharmaceutical industry. US President Donald Trump confirmed at the G7 summit in Évian, France…
The Indian pharmaceutical sector is undergoing a significant transformation in 2026, driven by landmark regulatory reforms from the Central Drugs Standard Control Organization (CDSCO), new clinical trial fast-track rules, updated…
The United States Food and Drug Administration (USFDA) has approached Indian pharmaceutical manufacturers to address a critical shortage of ifosfamide, a chemotherapy drug essential for treating testicular cancer, lung cancer,…